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Research
Diethylstilbestrol (DES) is a synthetic estro-
gen that was prescribed to > 2 million preg-
nant women in the mid-1900s. In later years,
it was discovered to be associated with the
occurrence of vaginal clear cell adeno-
carcinoma (Herbst et al. 1971), anatomic
abnormalities of the reproductive tract
(Stillman 1982), and poor reproductive out-
comes in daughters (Beral and Colwell 1981;
Kaufman et al. 2000; Palmer et al. 2001).
DES exposure in utero may also exert long-
term effects on female endocrine function,
possibly leading to permanent dysregulation
of the hypothalamic–pituitary–ovarian axis
and alterations in hormone biosynthesis in
adult women (Assies 1991; Peress et al. 1982;
Wu et al. 1980). Although the effect of DES
on plasma sex hormones has not been well
studied, elevated levels of serum testosterone
(Wu et al. 1980), but not luteinizing hormone
(LH) (Peress et al. 1982; Wu et al. 1980), prog-
esterone (Wu et al. 1980), or estrogens (Peress
et al. 1982; Wu et al. 1980), have been docu-
mented in DES daughters. Levels of follicle-
stimulating hormone (FSH) were elevated in
DES-exposed women in one study, but no
differences were found in LH or the ratio of
FSH to LH (Peress et al. 1982); another study
found no difference in FSH levels (Wu et al.
1980). Animal data show that in vitro produc-
tion of testosterone, total estrogen, and prog-
esterone by ovarian tissue was significantly
greater in female mice exposed prenatally to
DES, at all ages studied (Haney et al. 1984). 
Secondary sex ratio (proportion of male
births)—a prevalence measure that reflects
both sex programming at the time of concep-
tion and survival until birth—may be influ-
enced by exposure to endocrine disruptors
such as DES. In humans, several studies have
examined the relation between preconceptual
exposure to endocrine-disrupting compounds
and secondary sex ratio, but most associations
were observed in men and were mixed in
direction (James 2006). With respect to
maternal exposure, a significant decrease in sex
ratio was found in studies of polychlorinated
biphenyls (PCBs) (Weisskopf et al. 2003) and
mercury (Sakamoto et al. 2001), but the
majority of studies have been null, including
those that examined maternal exposure to
dioxin (Mocarelli et al. 2000; Rogan et al.
1999; Ryan et al. 2002; Yoshimura et al.
2001), PCBs (del rio Gomez et al. 2002;
Karmaus et al. 2002; Taylor et al. 2006;
Taylor et al. 1989), lead (Jarrell et al. 2006),
and dichlorodiphenyltrichloroethane (DDT)
(Cocco et al. 2006; Karmaus et al. 2002).
Moreover, dose and timing of exposure have
been incompletely characterized in many
studies, and little is known about the relation
of these chemicals to the maternal endogenous
hormonal milieu. For instance, PCBs have
estrogenic, antiestrogenic, and androgenic
properties (Bonefeld-Jorgensen et al. 2001),
making the direction and magnitude of their
effects difficult to predict. In a small study of
preconception maternal PCB concentrations
that stratified by hormonal activity of the
PCB, Taylor et al. (2006) found that the odds
of a male birth were elevated among women
exposed to estrogenic but not antiestrogenic
PCBs. Although not statistically significant,
these results suggest that PCBs have different
biologic effects depending on their underlying
hormonal activity.
A prevailing hypothesis is that endocrine
disruptors such as DES may affect secondary
sex ratio through changes in hormonal con-
centrations around the time of conception
(James 1987). In women, high levels of
gonadotropins (FSH and LH) and proges-
terone are hypothesized to change the ratio
toward more girls, whereas high testosterone
and estrogen levels change the ratio toward
more boys (James 1987). Another hypothe-
sis, the “over-ripeness ovopathy” theory
(Jongbloet 2004), postulates that sex ratio is
influenced by both oocyte maturation and the
quality of cervical mucus, with nonoptimal
hormonal modulation favoring male-biased
progeny. Nonoptimal liquefaction of cervical
mucus may facilitate differential migration of
sperm, with increased fertilization by Y-bear-
ing sperm because the head, length, perimeter,
and area are significantly smaller and the neck
and tail are shorter in Y-bearing sperm than in
X-bearing sperm (Cui 1997). Because concur-
rence of both oocyte maturation and cervical
mucus liquefaction is modulated by estrogens
Address correspondence to L.A. Wise, Slone
Epidemiology Center, 1010 Commonwealth Ave.,
4th Floor, Boston, MA 02215 USA. Telephone:
(617) 734-6006. Fax: (617) 738-5119. E-mail:
lwise@slone.bu.edu
This study was supported by grants N01-CP-21168,
N01-CP-51017, and N01-CP-01289 from the
National Cancer Institute. 
The authors declare they have no competing
financial interests.
Received 9 March 2007; accepted 28 June 2007.
Secondary Sex Ratio among Women Exposed to Diethylstilbestrol in Utero
Lauren A. Wise,1 Julie R. Palmer,1 Elizabeth E. Hatch,2 Rebecca Troisi,3,4 Linda Titus-Ernstoff,3 Arthur L. Herbst,5
Raymond Kaufman,6 Kenneth L. Noller,7 and Robert N. Hoover4
1Slone Epidemiology Center, Boston University, Boston, Massachusetts, USA; 2Department of Epidemiology, Boston University School
of Public Health, Boston, Massachusetts, USA; 3Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New
Hampshire, USA; 4Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of
Health and Human Services, Bethesda, Maryland, USA; 5Department of Obstetrics and Gynecology, University of Chicago, Chicago,
Illinois, USA; 6Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA; 7Department of Obstetrics
and Gynecology, New England Medical Center, Boston, Massachusetts, USA
BACKGROUND: Diethylstilbestrol (DES), a synthetic estrogen widely prescribed to pregnant women
during the mid-1900s, is a potent endocrine disruptor. Previous studies have suggested an associa-
tion between endocrine-disrupting compounds and secondary sex ratio. 
METHODS: Data were provided by women participating in the National Cancer Institute (NCI)
DES Combined Cohort Study. We used generalized estimating equations to estimate odds ratios
(ORs) and 95% confidence intervals (CIs) for the relation of in utero DES exposure to sex ratio
(proportion of male births). Models were adjusted for maternal age, child’s birth year, parity, and
cohort, and accounted for clustering among women with multiple pregnancies.
RESULTS: The OR for having a male birth comparing DES-exposed to unexposed women was 1.05
(95% CI, 0.95–1.17). For exposed women with complete data on cumulative DES dose and timing
(33%), those first exposed to DES earlier in gestation and to higher doses had the highest odds of
having a male birth. The ORs were 0.91 (95% C, 0.65–1.27) for first exposure at ≥ 13 weeks gesta-
tion to < 5 g DES; 0.95 (95% CI, 0.71–1.27) for first exposure at ≥ 13 weeks to ≥ 5 g; 1.16 (95%
CI, 0.96–1.41) for first exposure at < 13 weeks to < 5 g; and 1.24 (95% CI, 1.04–1.48) for first
exposure at < 13 weeks to ≥ 5 g compared with no exposure. Results did not vary appreciably by
maternal age, parity, cohort, or infertility history.
CONCLUSIONS: Overall, no association was observed between in utero DES exposure and secondary
sex ratio, but a significant increase in the proportion of male births was found among women first
exposed to DES earlier in gestation and to a higher cumulative dose.
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Environ Health Perspect 115:1314–1319 (2007). doi:10.1289/ehp.10246 available via
http://dx.doi.org/ [Online 28 June 2007]
before the midcycle, any perturbations to the
endogenous estrogenic milieu caused by
endocrine disruptors may theoretically affect
sex ratio (Jongbloet 2004). 
To our knowledge, there are no studies of
secondary sex ratio in women exposed to DES,
either prenatally or preconceptually, and most
animal studies of this association are null.
Specifically, studies in female mice (Honma
et al. 2002; Suzuki et al. 2002), rats (Odum
et al. 2002), and Chinese rare minnows
(Zhong et al. 2005) have found no association
between prenatal DES exposure and secondary
sex ratio, whereas studies in rats exposed pre-
conceptually to DES had an increased propor-
tion of male offspring (Sharpe et al. 1995).
We evaluated the association between
in utero DES exposure in women and the sec-
ondary sex ratio of their offspring in a large
collaborative study of participants with and
without documented exposure to DES. Based
on previous studies of sex steroid hormone lev-
els in women exposed in utero to DES and the
possible influence of these hormones on sex
ratio (James 1987), we hypothesized that DES-
exposed women would have a higher propor-
tion of male offspring than unexposed women.
Materials and Methods
Study population.The National Cancer
Institute (NCI) DES Combined Cohort
Study began in 1992 and includes four indi-
vidual cohorts of DES-exposed and unexposed
women that combine participants from several
field centers. The methods of the original
studies from which these cohorts were assem-
bled have been described elsewhere (Bibbo
et al. 1977; Colton et al. 1993; Dieckmann
et al. 1953; Horne and Kundsin 1985;
Labarthe et al. 1978). Briefly, participants
from three cohorts originally identified
for study during the 1950s–1970s—the
Diethylstilbestrol Adenosis Project (DESAD;
Labarthe et al. 1978), Dieckmann (Bibbo
et al. 1977; Dieckmann et al. 1953), and
Horne (Horne and Kundsin 1985)—were
traced and contacted for follow-up by the
NCI. The Dieckmann cohort study was a
clinical trial designed to test the efficacy of
DES in preventing adverse pregnancy out-
comes among women receiving routine prena-
tal care at the University of Chicago (Chicago,
IL). The DESAD and Horne cohorts were
derived from clinic populations. A fourth
cohort, the Women’s Health Study (WHS),
included the female offspring of women who
had participated in a 1970s health study of
DES-exposed and unexposed mothers. The
study protocol was approved by the human
subjects committees at the field centers and
by the NCI. Women provided informed con-
sent by completing and returning the mailed
questionnaires, or by participating in a
telephone interview. 
From the four cohorts, 7,439 daughters
were identified in 1992 as eligible for follow-
up. Of these, 84 were deceased, and 804 had
refused further contact during the original
cohort studies or were untraceable. In 1994,
6,551 study participants (88% of the original
surviving cohort) were contacted by mail and
were sent a baseline questionnaire eliciting
information on reproductive and contracep-
tive history, lifestyle and behavioral factors,
medical conditions, medication use, and
health care utilization. Participants were
called for a telephone interview if they did not
respond to two mailed questionnaires. In
1997, a follow-up questionnaire was sent to
update reproductive and medical informa-
tion. A total of 5,707 (87%) participants
responded to the 1994 questionnaire (3,946
exposed and 1,761 unexposed), and 5,579
(85%) responded to the 1997 questionnaire
(3,893 exposed and 1,686 unexposed). For
the present study, we included women who
completed at least the 1994 questionnaire.
We then excluded nulliparous women [1,433
(41%) exposed and 481 (27%) unexposed],
parous women who did not give information
on offspring sex [16 (< 1%) exposed and 5
(< 1%) unexposed], and women who reported
multifetal births but no singletons [1 (< 1%)
exposed and 0 (< 1%) unexposed].
Assessment of exposure, outcome, and
covariates. DES exposure status was verified
in all cohorts by medical record. The com-
pleteness of data on DES dose and gestational
timing of first exposure varied across the four
cohorts. Data on DES dose and timing were
carefully documented in the Dieckmann
cohort, with participants being exposed to
high cumulative doses of DES (median
cumulative dose, ~ 12 g) in adherence to the
regimen of Smith and Smith (1949). Women
in the Horne cohort were generally given high
doses of DES, and records of dose and timing
were available on almost all women. Exposure
in the DESAD cohort was difficult to esti-
mate because of incomplete information from
medical records. In this cohort, estimates
ranged from a median cumulative dose of
approximately 1.5–2.5 g at Baylor College of
Medicine (Houston, TX) and the Mayo
Clinic (Rochester, MN) to 8.5 g at the
Boston Lying In Hospital (Boston, MA)
(Labarthe et al. 1978). Data on dose and tim-
ing were unavailable in the WHS cohort. 
Information on DES dose was available
for 36% of exposed women. We used 5 g as a
cutpoint for “low” versus “high” dose because
the distribution was bimodal, with peaks at
about 2 g and 12 g. The cohorts included
women from several regions of the United
States. As regional DES prescribing practices
were similar, we conducted a secondary analy-
sis in which women with missing data on dose
were assigned an imputed value based on the
median dose for their specific field center.
Assigned doses were as follows: Dieckmann,
12.4 g; Horne, 10.4 g; Boston/DESAD, 8.5 g;
California/DESAD, 7.9 g; Baylor/DESAD,
2.6 g; Wisconsin/DESAD, 3.2 g; and
Mayo/DESAD, 1.5 g.
Gestational age at first DES exposure (in
weeks), available for 74% of exposed women,
was evaluated to assess whether biological sus-
ceptibility was related to timing of exposure.
Although gestational age at first exposure
ranged considerably within the cohorts, mean
values were generally lower (i.e., earlier) in the
Horne cohort. In cross-tabulations of dose
and timing, the data were dichotomized at
13 weeks gestational age because the first
trimester represents a period of heightened
susceptibility for the developing fetal repro-
ductive system (Sadler 2004). 
Information on DES dose and timing was
available for 33% of exposed women: 100% of
Dieckmann participants, 30% of DESAD,
70% of Horne, and 0% of WHS. Women
with complete data on dose and timing were
more likely than those without complete data
to be younger (year of birth 1960 or later:
18.2% vs. 11.5%), report a history of infertility
(41.3% vs. 33.3%), and be primiparous
(34.5% vs. 27.9%). No significant differences
were found with respect to maternal age at first
birth, age at menarche, education, body mass
index (BMI), or smoking status. 
On both the 1994 and 1997 question-
naires, women reported the outcome of each
pregnancy (singleton vs. multiple live birth,
stillbirth, spontaneous abortion, induced
abortion, and other), the sex of each birth,
and the date of the child’s birth. Infertility
history was elicited on the 1994 questionnaire
using two commonly employed definitions:
whether the participant ever tried to become
pregnant for ≥ 12 months without success,
and whether the participant ever sought med-
ical assistance for infertility from a health care
provider. Women were also asked if they had
ever used fertility drugs.
Statistical methods. Participants were
allowed to contribute more than one birth to
the analysis. Analyses were restricted to 7,732
singleton live births with complete informa-
tion on offspring sex and birth date (4,968
exposed and 2,764 unexposed). We estimated
odds ratios (ORs) and 95% confidence inter-
vals (CIs) for the association of prenatal DES
exposure with secondary sex ratio using gen-
eralized estimating equations (GEE) to
account for nonindependence (Liang and
Zeger 1993). ORs overestimate prevalence
ratios when the outcome is common, as was
the case in our study. Nevertheless, we pre-
sent ORs for comparability with other studies
of secondary sex ratio.
We considered maternal age, cigarette
smoking, calendar year of child’s birth, parity
Prenatal DES exposure and secondary sex ratio
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(i.e., birth order), and the use of fertility drugs
as potential confounders. Factors associated
with DES exposure that changed the OR by
> 2% were included in the final regression
models. Based on these criteria, multivariable
models controlled for maternal age at concep-
tion (< 25, 25–29, 30–34, 35–39, ≥ 40 years),
parity (1, 2, ≥ 3), and calendar year of child’s
birth (before 1980, 1980–1984, 1985–1989,
1990 or later). Models were further adjusted
for cohort (DESAD, Dieckmann, Horne,
WHS) because of cohort-related differences in
study methodology and participant recruit-
ment. Tests for trend by dose or timing were
performed by adding to the regression model a
single ordinal term coded as 0, 1, and 2 for no
DES, low dose, and high dose, or 0, 1, 2, and
3 for no DES, first exposure at 13 weeks or
later, 9–12 weeks, and before 9 weeks, respec-
tively (Breslow and Day 1987). Because
plasma levels of endogenous estrogens have
been shown to decrease with increasing age
(Dorgan et al. 1995) and parity (Bernstein
et al. 1986), we evaluated whether maternal
age (< 30 vs. ≥ 30 years) and parity (1 vs. ≥ 2
live births) modified the association between
DES and sex ratio. We also examined inter-
action by cohort. Likelihood ratio tests were
used to evaluate statistical interaction by com-
paring models with and without cross-product
terms between DES exposure and covariates of
interest. 
Finally, it is well established that in utero
DES exposure is associated with decreased
fertility (Kaufman et al. 2000; Palmer et al.
2001). Although GEE analyses that include
multiple births per mother provide additional
statistical power, the use of all births could
conceivably bias results toward the null if the
influence of DES varies among exposed
women. For example, if there are women who
are less sensitive to the effects of DES, and the
effect of DES on parity is related to its effect
on sex ratio, then the GEE approach may
overrepresent DES-exposed women who are
less sensitive to its effects (e.g., multiparous
women). To address this concern, we per-
formed a separate logistic regression analysis
among first-borns only (i.e., one birth per
mother), which may represent a less biased
sample. Analyses were carried out using SAS
statistical software (SAS Institute Inc. 2004).
Results
Women exposed to DES in utero were slightly
younger, more educated, more likely to report
a history of infertility and use fertility drugs,
and less likely to have ever smoked cigarettes
than unexposed women (Table 1). Exposed
and unexposed women were similar with
respect to BMI at 20 years of age, ever use of
oral contraceptives, sexual history, and alcohol
consumption. Over 96% of women were
white (data not shown). 
Table 2 shows the association between
prenatal DES exposure and secondary sex
ratio, overall and according to DES dose and
gestational age at first exposure. DES-exposed
women gave birth to 2,607 boys and 2,361
girls (sex ratio = 0.525), and unexposed
women gave birth to 1,406 boys and 1,358
girls (sex ratio = 0.509), resulting in an unad-
justed OR for having a male birth of 1.07
(95% CI, 0.97–1.17). After adjustment for
maternal age, calendar year of child’s birth,
parity, and study cohort, the OR for having a
male infant comparing exposed to unexposed
women was 1.05 (95% CI, 0.95–1.17). 
The odds of conceiving a male birth
appeared to increase with increasing DES dose
in both unadjusted and adjusted models
(p-trend = 0.038). Among women with com-
plete information on dose, the fully adjusted
ORs for women prenatally exposed to < 5 g
and to ≥ 5 g relative to unexposed women were
1.12 (95% CI, 0.95–1.33) and 1.16 (95% CI,
0.98–1.36), respectively. Given that only a
small proportion of exposed women had dose
information (36%), we repeated these analyses
after assigning women with missing dose the
median value of their study center. With dose
imputation, the fully adjusted ORs were 1.05
(95% CI, 0.92–1.19) for < 5 g and 1.10 (95%
CI, 0.97–1.26) for ≥ 5 g relative to no exposure
(p-trend = 0.124). 
The odds of conceiving a male birth
increased slightly with decreasing gestational
age at first DES exposure, but there was no
statistical evidence of a trend (p-trend =
0.186). Among women with complete infor-
mation on timing of DES exposure, the fully
adjusted ORs for first exposure at ≥ 13, 9–12,
and < 9 weeks of gestation relative to no
exposure were 1.03 (95% CI, 0.89–1.18),
1.06 (95% CI, 0.92–1.23), and 1.08 (95%
CI, 0.93–1.24), respectively. 
Women first exposed to DES earlier in
gestation and at higher doses had the highest
odds of having a male birth (Table 2).
Among women with complete information
on DES dose and timing (33%), the fully
adjusted ORs for having a male birth were
0.91 (95% CI, 0.65–1.27) for first exposure
Wise et al.
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Table 1. Characteristics of parous women with and
without prenatal DES exposure (1994).a
Prenatal exposure to DES
Yes No
Characteristic (n = 2,496) (n = 1,275)
Cohort
DESAD 2,090 (83.7) 607 (47.6)
Dieckmann 137 (5.5) 156 (12.2)
Horne 70 (2.8) 46 (3.6)
WHS 199 (8.0) 466 (36.6)
Year of birth
Before 1950 463 (18.5) 374 (29.3)
1950–1954 1,063 (42.6) 537 (42.1)
1955–1959 629 (25.2) 300 (23.6)
1960 or later 341 (13.7) 64 (5.0)
Education
High school or less 393 (15.8) 292 (22.9)
Some college 644 (25.9) 353 (27.7)
College 840 (33.7) 374 (29.4)
Graduate school 612 (24.6) 254 (20.0)
Age at menarche (years)
< 12 394 (15.8) 223 (17.5)
12–13 1,510 (60.6) 737 (57.9)
≥ 14 589 (23.6) 313 (24.6)
BMI at 20 years of age (kg/m2)
< 20 1,051 (43.4) 522 (42.3)
20–24 1,200 (49.6) 626 (50.7)
≥ 25 169 (7.0) 86 (7.0)
Use of fertility drugs
Never 2,108 (84.7) 1,185 (93.0)
Ever 382 (15.3) 89 (7.0)
Smoking status
Never 1,442 (58.0) 640 (50.3)
Ever 1,046 (42.0) 632 (49.7)
No. of live births
1 751 (30.1) 283 (22.2)
2 1,191 (47.7) 631 (49.5)
≥ 3 554 (22.2) 361 (28.3)
Infertility history
No 1,583 (64.0) 1,030 (81.5)
Yesb 889 (36.0) 234 (18.5)
aValues are expressed as number (column percent); num-
bers may not sum to total because of missing data. bDefined
as having tried to conceive for ≥ 12 months without success
or having sought medical help for infertility. 
Table 2. Offspring sex ratio in relation to prenatal DES exposure, overall and by timing and dose.
No. of children Proportion Unadjusted Adjusted p-Value, test 
Male Female male OR (95% CI) OR (95% CI)a for trenda
Unexposed 1,406 1,358 0.509 1.00b 1.00b —
Exposed 2,607 2,361 0.525 1.07 (0.97–1.17) 1.05 (0.95–1.17)
DES dose (g)
< 5 444 378 0.540 1.13 (0.96–1.33) 1.12 (0.95–1.33) 0.038
≥ 5 494 405 0.550 1.18 (1.01–1.37) 1.16 (0.98–1.36)
Gestational age at first exposure (weeks)
≥ 13 683 632 0.519 1.05 (0.91–1.19) 1.03 (0.89–1.18) 0.186
9–12 584 516 0.531 1.09 (0.95–1.26) 1.06 (0.92–1.23)
< 9 687 609 0.530 1.09 (0.95–1.25) 1.08 (0.93–1.24)
Dose and timing
< 5 g, ≥ 13 weeks 98 101 0.493 0.94 (0.67–1.30) 0.91 (0.65–1.27) —
≥ 5 g, ≥ 13 weeks 103 102 0.502 0.98 (0.74–1.30) 0.95 (0.71–1.27)
< 5 g, < 13 weeks 293 241 0.549 1.17 (0.97–1.41) 1.16 (0.96–1.41)
≥ 5 g, < 13 weeks 369 282 0.567 1.26 (1.07–1.50) 1.24 (1.04–1.48)
Data on dose, timing, and both dose and timing were available for 36%, 74%, and 33% of women, respectively. 
aAdjusted for maternal age at conception, year of child’s birth, parity, and cohort. bReference group for all column
comparisons.
at ≥ 13 weeks to < 5 g, 0.95 (95% CI,
0.71–1.27) for first exposure at ≥ 13 weeks to
≥ 5 g, 1.16 (95% CI, 0.96–1.41) for first
exposure at < 13 weeks to < 5 g, and 1.24
(95% CI, 1.04–1.48) for first exposure at
< 13 weeks to ≥ 5 g, compared with no expo-
sure. In analyses that imputed doses for
women with missing data, results were atten-
uated but generally similar. The fully adjusted
ORs for having a male birth were 1.03 (95%
CI, 0.86–1.22) for first exposure at ≥ 13
weeks to < 5 g, 1.03 (95% CI, 0.84–1.23) for
first exposure at ≥ 13 weeks to ≥ 5 g, 1.02
(95% CI, 0.88–1.18) for first exposure at
< 13 weeks to < 5 g, and 1.13 (95% CI,
0.97–1.31) for first exposure at < 13 weeks to
≥ 5 g compared with no exposure.
Although the association between DES
and sex ratio appeared to be stronger for par-
ticipants in the Horne cohort (Table 3), the
association was based on small numbers and
was not statistically different from the other
cohorts. Dose and timing results among the
DESAD cohort were consistent with those
found in the overall sample. Dose and timing
results could not be assessed in the WHS,
Dieckmann, and Horne cohorts either because
of lack of data (i.e., WHS cohort) or because
of limited variation in dose (i.e., all of the
Dieckmann participants received > 5 g) or
timing (i.e., all Horne participants were first
exposed to DES before 9 weeks of gestation). 
The adjusted OR for the association
between DES and sex ratio was similar among
women with (OR = 1.03; 95% CI, 0.83–1.29)
and without (OR = 1.03; 95% CI, 0.92–1.17)
a history of infertility, defined as women who
tried for ≥ 12 months to conceive without suc-
cess or sought medical assistance for infertility
(p-interaction = 0.975). Within the subgroup
of women with a history of infertility, the OR
was 1.00 among women who had used fertility
drugs (95% CI, 0.68–1.47) and 1.05 among
women who had not (95% CI, 0.80–1.37;
p-interaction = 0.744). Likewise, the associa-
tion between DES and sex ratio was similar
among women < 30 years of age at the time of
delivery (OR = 1.05; 95% CI, 0.91–1.20)
compared with those ≥ 30 years of age (OR =
1.06; 95% CI, 0.91–1.24; p-interaction =
0.952). With respect to parity status at the
time of birth, the adjusted OR was not signifi-
cantly different among primiparous women
(OR = 1.10; 95% CI, 0.95–1.28) compared
with multiparous women (OR = 1.02; 95%
CI, 0.88–1.17; p-interaction = 0.317). OR
estimates for dose and timing were similar
across these subgroups and showed no evi-
dence of statistical interaction (data not
shown). 
In analyses restricted to first births only,
overall and dose-specific results were generally
stronger than results among all births
(Table 4). The fully adjusted OR for having a
male birth was 1.37 (95% CI, 1.06–1.77) for
first exposure at < 13 weeks to ≥ 5 g compared
with no exposure.
Discussion
The present findings are based on the largest
study to date of U.S. women with docu-
mented intrauterine exposure to DES.
Although we found no overall association
between in utero DES exposure and secondary
sex ratio, DES-exposed women who were first
exposed earlier in gestation and to higher
doses gave birth to a significantly higher pro-
portion of males. If the developing female
reproductive system is more susceptible to
endocrine disruptors in the first trimester, the
stronger association observed for women
exposed to higher DES doses earlier in gesta-
tion is biologically plausible (Sadler 2004).
These findings are the first to suggest a link
between in utero DES exposure among
women and the sex ratio of their offspring. 
Previous research on maternal exposure to
endocrine disruptors and secondary sex ratio
has focused on exposure at times other than
the prenatal period. Although our finding of
an increased sex ratio among DES-exposed
women is not consistent with two positive
studies that found a significant decrease in sex
ratio after maternal exposure to polychlori-
nated biphenyls (PCBs) (Weisskopf et al.
2003) and mercury (Sakamoto et al. 2001), it
is consistent with a small study of preconcep-
tion maternal PCB concentrations (Taylor
et al. 2006). In the latter study, the odds of a
male birth were elevated among women in the
second (OR = 1.29) and third (OR = 1.48)
tertiles of estrogenic PCBs, whereas odds were
reduced among women in the highest tertile
(OR = 0.70) of antiestrogenic PCBs (Taylor
et al. 2006). Although the sample size was
small (n = 99) and the results were not statisti-
cally significant, the Taylor et al. (2006) study
suggests that maternal exposure to chemicals
with estrogenic properties might increase the
likelihood of a male birth.
An important limitation of the present
study is the high proportion of missing data
on dose and timing of DES exposure (67% of
exposed). A significant finding was observed
only among those exposed earlier in gestation
and to higher doses, but it is unclear whether
or how our results would have changed had
we acquired complete data on dose and tim-
ing. Among the exposed participants, the
male birth proportions for women who did
Prenatal DES exposure and secondary sex ratio
Environmental Health Perspectives • VOLUME 115 | NUMBER 9 | September 2007 1317
Table 4. Offspring sex ratio in relation to prenatal DES exposure, overall and by timing and dose, restricted
to first births. 
No. of children Proportion Unadjusted Adjusted p-Value, test 
Male Female male OR (95% CI) OR (95% CI)a for trenda
Unexposed 650 625 0.510 1.00b 1.00b —
Exposed 1,339 1,155 0.537 1.12 (0.97–1.28) 1.10 (0.95–1.28)
DES dose (g)
< 5 229 197 0.538 1.12 (0.90–1.39) 1.11 (0.88–1.40) 0.021
≥ 5 261 202 0.564 1.24 (1.00–1.54) 1.25 (1.00–1.57)
Gestational age at first exposure (weeks)
≥ 13 347 284 0.550 1.17 (0.97–1.42) 1.17 (0.95–1.44) 0.098
9–12 288 265 0.521 1.05 (0.86–1.28) 1.03 (0.83–1.28)
< 9 377 305 0.553 1.19 (0.99–1.43) 1.20 (0.98–1.47)
Dose and timing
< 5 g, ≥ 13 weeks 54 49 0.524 1.06 (0.71–1.58) 1.03 (0.68–1.55) —
≥ 5 g, ≥ 13 weeks 48 50 0.490 0.92 (0.61–1.39) 0.92 (0.61–1.40)
< 5 g, < 13 weeks 147 130 0.531 1.09 (0.84–1.41) 1.09 (0.83–1.43)
≥ 5 g, < 13 weeks 200 142 0.585 1.35 (1.06–1.72) 1.37 (1.06–1.77)
Data on dose, timing, and both dose and timing were available for 36%, 75%, and 33% of women, respectively. 
aAdjusted for maternal age at conception, year of child’s birth, and cohort. bReference group for all column comparisons.
Table 3. Offspring sex ratio in relation to prenatal DES exposure by study cohort.
No. of children Proportion Unadjusted Adjusted p-Value, test 
Cohort Male Female male OR (95% CI) OR (95% CI)a for interaction
DESAD
Unexposed 671 639 0.512 1.00b 1.00b —b
Exposed 2,204 1,990 0.526 1.05 (0.93–1.19) 1.06 (0.94–1.20)
Dieckmann
Unexposed 179 162 0.525 1.00b 1.00b 0.85
Exposed 146 121 0.547 1.10 (0.80–1.53) 1.08 (0.78–1.51)
Horne
Unexposed 34 48 0.415 1.00b 1.00b 0.14
Exposed 57 48 0.543 1.67 (0.94–2.99) 1.61 (0.86–3.02)
WHS
Unexposed 522 509 0.506 1.00b 1.00b 0.51
Exposed 200 202 0.498 0.97 (0.76–1.23) 0.95 (0.75–1.20)
aAdjusted for maternal age at conception, year of child’s birth, and parity. bReference group for interaction tests.
(0.543) and did not (0.516) have complete
data on dose and timing were both higher
than the unexposed (0.509), but the magni-
tude of the difference was noticeably higher in
women with complete data on dose and tim-
ing. Although these differences cannot be
downplayed, we believe it is unlikely that
missingness of data was related to both DES
dose (and timing) and the probability of a
male birth—conditions that would be neces-
sary for bias to occur. Analyses in which
women with missing dose were assigned to
the median dose of their field center produced
attenuated ORs, as would be expected under
random exposure misclassification, but the
estimates were largely consistent with the
main results. Moreover, when analyses were
restricted to first births only—a sample that
may be less biased because it is not over-
represented by multiparous women—overall
and dose-specific results were generally
stronger. Nonetheless, our limited data on
dose and timing should be taken into account
when interpreting our results.
Strengths of the present study include the
verification of DES exposure status by medi-
cal record and the determination of exposure
status before reporting of birth outcomes,
both of which reduce the potential for differ-
ential misclassification of exposure. It is
unlikely that knowledge of one’s DES expo-
sure influenced the reporting of offspring sex,
as there is no information in the lay press
about the influence of DES on secondary sex
ratio. Given that similar proportions of
exposed and unexposed women completed
the 1994 questionnaire (87%), and no differ-
ences were found in the baseline characteris-
tics of those who were and were not lost to
follow-up (data not shown), selection bias is
also an unlikely explanation of our results.
Finally, in contrast to most studies of
endocrine-disrupting compounds, we had a
spectrum of data on dose and timing, which
allowed for an examination of dose–response
relations.
An association between in utero DES expo-
sure and secondary sex ratio in women is bio-
logically plausible. According to James (1987),
environmental toxicants may influence sec-
ondary sex ratio via changes in maternal hor-
monal concentrations around the time of
conception, with high concentrations of testos-
terone and estrogen increasing the probability
of a son and high concentrations of gonado-
tropins and progesterone increasing the proba-
bility of a daughter. Another theory postulates
that sex ratio is influenced by both oocyte mat-
uration and the quality of cervical mucus
(Jongbloet 2004). Given that both maturation
and cervical liquefaction are influenced by
estrogens before the midcycle, toxicants with
antiestrogenic properties might be expected to
increase the sex ratio. 
Studies of prenatal DES exposure and its
long-term effects on endogenous hormones are
limited. The sole animal study of this relation
showed that in vitro secretion of testosterone,
total estrogen, and progesterone in ovarian
tissue was significantly increased in female
mice exposed prenatally to DES (Haney et al.
1984). However, tissue production in vitro
may not necessarily reflect total secretion of
these hormones in vivo, especially because the
ovaries of exposed mice were smaller than
those of unexposed mice. Only two human
studies have examined differences in
gonadotropins and sex hormones in associa-
tion with in utero DES exposure (Peress et al.
1982; Wu et al. 1980), reporting that DES
daughters had elevated levels of serum testos-
terone (Wu et al. 1980) but not estrogens
(Peress et al. 1982; Wu et al. 1980), proges-
terone (Wu et al. 1980), or LH (Peress et al.
1982; Wu et al. 1980). Higher FSH levels
among DES-exposed women were found only
by Peress et al. (1982), but the FSH to LH
ratio was unaffected. In the study by Wu et al.
(1980), differences in testosterone were great-
est in the postovulatory and perimenstrual
phases of the menstrual cycle, suggesting that
the corpus luteum of DES daughters produces
more testosterone. Under James’ hormonal
hypothesis (James 1987), elevated testosterone
levels around the time of conception would be
expected to increase the proportion of male
births, as found in the present study. In con-
trast, the “over-ripeness ovopathy” hypothesis
(Jongbloet 2004) seems less plausible given
that no differences in plasma estrogen levels
were observed between DES-exposed and
unexposed women in either study (Peress et al.
1982; Wu et al. 1980).
The interpretation of the literature on sec-
ondary sex ratio has been subject to debate,
particularly with respect to the veracity and
significance of the declining sex ratios reported
in several countries worldwide (Bonde and
Wilcox 2007; Davis et al. 1998). Whereas
some epidemiologists have argued for the use
of sex ratio as a sentinel health indicator in
response to environmental exposures (Davis
et al. 1998), others have questioned its value,
citing its vulnerability both to false positive
reports and publication bias (Bonde and
Wilcox 2007).
In conclusion, although we found no
overall association between DES exposure
in utero and secondary sex ratio, a small
increase in the proportion of male births was
observed among women who were first
exposed earlier in gestation and to higher
doses. These results warrant confirmation in
other study populations with data on DES
dose and timing. If the association is real, it
adds to the growing concern held by some
epidemiologists that endocrine disruptors
may affect secondary sex ratio in humans.
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